Approche diagnostique et thérapeutique de la vasculopathie polypoïdale choroïdienne. Recommandations de la Fédération France Macula

PURPOSE: To update the medical literature on the diagnostic and therapeutic approach to polypoidal choroidal vasculopathy (PCV) and to propose a treatment algorithm in agreement with French market approval, supported by the France Macula Federation (FFM). METHODS: Literature review and expert opinion. RESULTS: The diagnosis of PCV is based on multimodal imaging, including indocyanine green angiography (ICGA), which is considered the gold standard for the diagnosis of PCV. Regarding the therapeutic management of PCV, the FFM recommends treating PCV first-line either by monotherapy with intra-vitreal anti-vascular endothelial growth factor (anti-VEGF) injections, or by a combined treatment of photodynamic therapy (PDT) with Verteporfin and intra-vitreal anti-VEGF injections, depending on the location of the PCV.Objectif : Mettre à jour la littérature médicale sur l’approche diagnostique et thérapeutique de la vasculopathie polypoïdale choroïdienne (VPC) et proposer un algorithme de traitement adapté aux recommandations françaises et à la bonne utilisation des autorisations de mise sur le marché (AMM), soutenu par la Fédération France Macula (FFM).Méthodes : Analyse de la littérature et avis d’experts.Résultats : Le diagnostic de la VPC repose sur l’imagerie multimodale, néanmoins, l’angiographie au vert d’indocyanine est recommandée par la FFM et reste le Gold Standard. Concernant la prise en charge thérapeutique de la VPC, la FFM recommande de traiter la VPC en 1ère intention soit par monothérapie avec des injections intra-vitréennes d’anti-VEGF, soit par traitement combiné associant photothérapie dynamique (PDT) à la Verteporfine et injections intra-vitréennes d’anti-VEGF en fonction de la localisation de la VPC

Synthesis of supported ZSM-5 nanoparticles

International audienceThe influence of the support on the nucleation of ZSM-5 nanoparticles has been studied for three supports: γ-alumina, zirconia and carbon nanotubes (CNT). While zeolite nucleation was suppressed in presence of alumina and strongly delayed in presence of zirconia, it occurred without delay in presence of CNT. These differences are explained by the partial dissolution of the support (for alumina and zirconia supports) that modify the composition of the zeolite nucleation solution. For the CNT/zeolite sample, the obtained composite contains about 60 wt% of zeolite and develops a surface area of 776 m 2 .g-1

Antimicrobial and Anti-Inflammatory Activity of Chitosan–Alginate Nanoparticles: A Targeted Therapy for Cutaneous Pathogens

Advances in nanotechnology have demonstrated potential application of nanoparticles for effective and targeted drug delivery. Here, we investigated the antimicrobial and immunological properties and the feasibility of using nanoparticles to deliver antimicrobial agents to treat a cutaneous pathogen. Nanoparticles synthesized with chitosan and alginate demonstrated a direct antimicrobial activity in vitro against Propionibacterium acnes, the bacterium linked to the pathogenesis of acne. By electron microscopy imaging, chitosan-alginate nanoparticles were found to induce disruption of the P. acnes cell membrane, providing a mechanism for the bactericidal effect. The chitosan-alginate nanoparticles also exhibited anti-inflammatory properties as they inhibited P. acnes induced inflammatory cytokine production in human monocytes and keratinocytes. Furthermore, benzoyl peroxide, a commonly used anti-acne drug, was effectively encapsulated in the chitosan-alginate nanoparticles and demonstrated superior antimicrobial activity against P. acnes compared to benzoyl peroxide alone while demonstrating less toxicity to eukaryotic cells. Together, these data suggest the potential utility of topical delivery of chitosan-alginate nanoparticle encapsulated drug therapy for the treatment of dermatologic conditions with infectious and inflammatory components

Hormonal and pheromonal modulation of the extended amygdala: implications for social behaviour.

Volume 1 Chapitre 12 Mention d'édition : 2International audienc